ADARx scores upsized $446M IPO, while City maps out Nasdaq plans
Why now
Thesis: Biotech IPO window showing signs of life
Catalyst to watch: Pricing and aftermarket performance
Main risk: Weak debut cools the window
Why it matters
A biotech IPO upsizing signals reopening risk appetite for new listings in the sector.
Sources
- googlenews · news.google.com · 2026-09-25 06:46 UTC
- googlenews · news.google.com · 2026-09-25 06:46 UTC